{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["42(10)"],"submitter":["Touzeau C"],"funding":["Johnson & Johnson"],"pubmed_abstract":["Introduction
Ciltacabtagene autoleucel (cilta-cel) is approved for relapsed or refractory multiple myeloma (RRMM). In the CARTITUDE-4 study (NCT04181827), cilta-cel demonstrated superior efficacy versus pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone in patients with RRMM after 1-3 prior lines of therapy (LOT). We conducted an indirect treatment comparison to understand the comparative efficacy of cilta-cel versus real-world (RW) physician's choice of treatment for lenalidomide-refractory MM.Methods
De-identified data from the Flatiron Health MM cohort registry (January 2020 to May 2024) were compared with data from CARTITUDE-4 (data cutoff May 1, 2024). Key eligibility criteria for CARTITUDE-4 were used to match patients from the"],"journal":["Advances in therapy"],"pagination":["5023-5041"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12474644"],"repository":["biostudies-literature"],"pubmed_title":["Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma."],"pmcid":["PMC12474644"],"pubmed_authors":["Touzeau C","Lee S","Zamagni E","Mina R","Yeh TM","Dytfeld D","Sidana S","Corradini P","Nair S","Leleu X","Slaughter A","Zhao M","Puig N","Delforge M","Khan AM","Schecter JM","Lipe B","Lonardi C","Karlin L","He J","Weisel K","Chen D","Mendes J","Roeloffzen W","Dhakal B","Lendvai N"],"additional_accession":[]},"is_claimable":false,"name":"Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma.","description":"Introduction
Ciltacabtagene autoleucel (cilta-cel) is approved for relapsed or refractory multiple myeloma (RRMM). In the CARTITUDE-4 study (NCT04181827), cilta-cel demonstrated superior efficacy versus pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone in patients with RRMM after 1-3 prior lines of therapy (LOT). We conducted an indirect treatment comparison to understand the comparative efficacy of cilta-cel versus real-world (RW) physician's choice of treatment for lenalidomide-refractory MM.Methods
De-identified data from the Flatiron Health MM cohort registry (January 2020 to May 2024) were compared with data from CARTITUDE-4 (data cutoff May 1, 2024). Key eligibility criteria for CARTITUDE-4 were used to match patients from the","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-03T23:24:04.465Z","creation":"2026-05-03T03:10:49.26Z"},"accession":"S-EPMC12474644","cross_references":{"pubmed":["40768190"],"doi":["10.1007/s12325-025-03308-2"]}}